AU2021396381A1 - Compositions and methods comprising sfrp2 antagonists - Google Patents

Compositions and methods comprising sfrp2 antagonists Download PDF

Info

Publication number
AU2021396381A1
AU2021396381A1 AU2021396381A AU2021396381A AU2021396381A1 AU 2021396381 A1 AU2021396381 A1 AU 2021396381A1 AU 2021396381 A AU2021396381 A AU 2021396381A AU 2021396381 A AU2021396381 A AU 2021396381A AU 2021396381 A1 AU2021396381 A1 AU 2021396381A1
Authority
AU
Australia
Prior art keywords
antibody
sfrp2
binding fragment
antigen
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021396381A
Other languages
English (en)
Inventor
Nancy DEMORE
Cam Patterson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Original Assignee
University of North Carolina at Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill filed Critical University of North Carolina at Chapel Hill
Publication of AU2021396381A1 publication Critical patent/AU2021396381A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2021396381A 2020-12-11 2021-12-10 Compositions and methods comprising sfrp2 antagonists Pending AU2021396381A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063124345P 2020-12-11 2020-12-11
US63/124,345 2020-12-11
PCT/US2021/062854 WO2022125927A1 (en) 2020-12-11 2021-12-10 Compositions and methods comprising sfrp2 antagonists

Publications (1)

Publication Number Publication Date
AU2021396381A1 true AU2021396381A1 (en) 2023-07-06

Family

ID=81974701

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021396381A Pending AU2021396381A1 (en) 2020-12-11 2021-12-10 Compositions and methods comprising sfrp2 antagonists

Country Status (10)

Country Link
US (2) US11873333B2 (https=)
EP (1) EP4259203A4 (https=)
JP (1) JP7747350B2 (https=)
KR (1) KR102934264B1 (https=)
CN (1) CN116744970A (https=)
AU (1) AU2021396381A1 (https=)
CA (1) CA3201893A1 (https=)
IL (1) IL303600A (https=)
MX (1) MX2023006777A (https=)
WO (1) WO2022125927A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102934264B1 (ko) 2020-12-11 2026-03-05 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 Sfrp2 길항제를 포함하는 조성물 및 방법
WO2025076318A1 (en) * 2023-10-06 2025-04-10 Musc Foundation For Research Development Compositions for modulating the kras pathway and methods of use thereof
CN117756910A (zh) * 2023-12-22 2024-03-26 首都医科大学附属北京口腔医院 Sfrp2功能多肽及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
EP0216846B2 (en) 1985-04-01 1995-04-26 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP3124497B1 (en) 2007-09-14 2020-04-15 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
JP2011523551A (ja) 2008-05-15 2011-08-18 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 血管形成の調節の新規ターゲット
WO2011119524A1 (en) 2010-03-22 2011-09-29 The University Of North Carolina At Chapel Hill Novel targets for regulation of angiogenesis
KR102318383B1 (ko) 2010-07-16 2021-10-27 아디맵 엘엘씨 항체 라이브러리
JP6072771B2 (ja) 2011-04-20 2017-02-01 メディミューン，エルエルシー Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
WO2015038882A1 (en) * 2013-09-13 2015-03-19 The University Of North Carolina At Chapel Hill Methods and compositions for tumor vasculature imaging and targeted therapy
KR102934264B1 (ko) 2020-12-11 2026-03-05 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 Sfrp2 길항제를 포함하는 조성물 및 방법

Also Published As

Publication number Publication date
KR20230118904A (ko) 2023-08-14
US12258388B2 (en) 2025-03-25
US11873333B2 (en) 2024-01-16
US20220204598A1 (en) 2022-06-30
IL303600A (en) 2023-08-01
WO2022125927A1 (en) 2022-06-16
CA3201893A1 (en) 2022-06-16
EP4259203A1 (en) 2023-10-18
EP4259203A4 (en) 2024-12-18
KR102934264B1 (ko) 2026-03-05
JP2023553938A (ja) 2023-12-26
JP7747350B2 (ja) 2025-10-01
US20240190949A1 (en) 2024-06-13
CN116744970A (zh) 2023-09-12
MX2023006777A (es) 2023-08-17

Similar Documents

Publication Publication Date Title
US12258388B2 (en) Compositions and methods comprising SFRP2 antagonists
EP3901175A1 (en) Anti-cd73 monoclonal antibody and application thereof
WO2020019135A1 (zh) 一种抗cd47抗体及其应用
CN107922503A (zh) 一种pdl‑1抗体、其药物组合物及其用途
KR20190117493A (ko) 항 pd-1 항체 및 그의 용도
KR20160108310A (ko) 암 치료를 위한 항-ceacam1 및 항-pd 항체를 포함하는 조성물
KR102678252B1 (ko) 재조합 이중특이적 항체
US12221490B2 (en) Antibodies against hEPCR
WO2023001303A1 (zh) 药物组合物及用途
AU2020339478A1 (en) Anti PD-L1 antibody and use thereof
EP4159764A1 (en) Anti-pdl1×egfr bispecific antibody
TW202126700A (zh) 一種融合蛋白及其應用
JP2025524390A (ja) 抗ｃｌｄｎ１８．２抗体並びにその医薬組成物及び使用
KR20230171452A (ko) Pd-1 및 tim-3을 표적으로 하는 이중특이적 항체
CN108431037A (zh) 抗myl9抗体
CN116323657B (zh) 同时靶向PD-L1和TGFβ的双功能分子及其医药用途
WO2022068894A1 (zh) 同时靶向pd-l1和vegf的双功能分子及其医药用途
US20220177593A1 (en) Anti-axl antibodies and methods of use thereof
CA3094763C (en) Anti-cd137 antibodies for combination with anti-pd-l1 antibodies
JP2022513036A (ja) がんを治療するための、抗ｃｅａｃａｍ６および抗ｐｄ－１抗体または抗ｐｄ－ｌ１抗体のいずれかの医薬組み合わせ
EP4174086A1 (en) Antibody specifically binding to lgals3bp, and use thereof
JP2020524527A (ja) ヒト腫瘍幹細胞をターゲティングするモノクローナル抗体及びその使用
RU2783685C2 (ru) Анти-pd-l1 антитело и его применение
CN113166264B (zh) 一种分离的抗原结合蛋白及其用途
WO2025124463A1 (zh) 抗her2的双特异性抗体及其应用